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Abstract
Background: Since chronic apical periodontitis (CAP) appears to be a risk factor for coronary heart disease, the aim
of the study was to determine the relationship between the size of CAP lesion and inflammatory markers (hsCRP,
IL-6, TNF-α), as well as lipids and lipoproteins (LpPLA2, apoAI, apoB level) in blood serum of patients with CAP.
Methods: The patients studied (n = 43) were divided into groups: patients under 50 and over 50 years of age, and
a separate subgroup of the oldest age with the largest size of CAP lesions. Apolipoprotein AI (apoAI) above 150 mg/dL
and below 150 mg/dL was used as an important criterion for the division of patients into groups. The CAP lesion size
was measured using the Kodak digital imaging system software. The control group consisted of clinically healthy
volunteers (n = 20) without CAP. Lipids were measured on a Siemens analyzer (Germany), apoAI, apoB, hsCRP
levels were determined by immunonephelometric method, using the Health Care Diagnostic Product (Siemens
GmbH, Germany), and IL-6, TNF-α and LpPLAG7 assay kits (ELISA, R&D Systems) were used.
Results: The findings suggested that in patients with CAP and their age increase, the CAP lesion size, the concentration
of inflammatory markers and LpPLA2 mass increased. Correlations between the CAP lesion size and LpPLA2 mass and
between the CAP lesion size and TG level in patients with apoAI 150 ≤mg/dL showed increase TG in atherogenic
apoB-containing triglyceride-rich lipoprotein and TC in cholesterol-rich lipoprotein. The patients with a low apoAI
and high LpPLA2 level can have a higher risk of odontogenic disease and progression of atherosclerosis and coronary
heart disease.
Conclusion: We have found a positive correlation between apoAI level and the CAP lesion size and a negative
correlation between LpPLA2 level and the CAP lesion size. The results suggest that apoAI and LpPLA2 in HDL
particles have antiinflammatory action and together can limit the CAP lesion size in patient with a higher apoAI
level. The literature data on the distribution of lipoprotein particles in subjects are still insufficient, so this problem
requires further studies.
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Background
Atherosclerosis is considered as an inflammation-
mediated process initiating the focal accumulation of
lipids into the arterial intima and driven by complex in-
teractions between leukocytes, platelets and cells of the
vessel wall [1]. So, the role of serum lipids and lipopro-
teins is significant in this inflammatory process [2, 3].
Inflammation occurs as a result of exposure of tissues
and organs to harmful stimuli such as microbial pathogens,
irritants, or toxic cellular components. Inflammation
processes involve the major cells of the immune system
[4]. Interleukin-6 (IL-6) is a cytokine, which plays an
important role in many chronic inflammatory diseases
[5]. The author’s previous findings had shown that
serum and gingival crevicular fluid (GCF) proinflammatory
cytokines such as TNF-α, IL-1b, and IL-6 levels may play
an important role in association with a periodontal disease
and hyperlipidemia [3]. The release of IL-6 from several
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cell types, including smooth muscle cells was induced by
TNF-α and IL-1. The effects of IL-6 and TNF-α on lipid
metabolism may develop endothelial generation of nitric
oxide in consequence of which are raising circulating con-
centrations of non-esterified fatty acids [6]. The effect of
IL-6 on platelets, fibrinogen concentrations, and coagula-
tion and of TNF-α on expression of plasminogen activator
inhibitor by hepatocytes, endothelial cells, and adipose tis-
sue may lead to a procoagulant state in such subjects [7].
Therefore, reduction of the inflammatory mediators such
as TNF-α and IL-6 (serum and/or GCF), which are also as-
sociated with both hyperlipidemia and periodontitis may
provide a further contribution to a two-way relationship
between periodontitis and hyperlipidemia [3, 8]. Oxidative
stress and atherogenic dyslipidaemia have synergistic im-
pact on atherosclerosis and cardiovascular diseases [9, 10].
In this context, lipoprotein associated phospholipase A2
(Lp- PLA2), an enzyme that has been shown to be a risk
factor for cardiovascular disease (CVD) and is believed
to be an independent CVD risk factor that is also involved
in degradation of the phospholipid mediator platelet-
activating factor (PAF) [11–13] was significantly reduced
by treatment of periodontitis [9, 14]. Unfortunately, the
mechanism by which these cytokines increase the serum
lipid and lipoprotein levels is unknown. Hence, a little in-
formation about the relationship between chronic apical
periodontitis (CAP) and lipoproteins is available. CAP is
defined as a persistent inflammation of tissues adjacent to
the apex of the tooth root. It is usually called asymptom-
atic because it probably does not produce any clinical
symptoms, but on radiographs destruction of the periapi-
cal tissues with possible resorption of the root and bone is
noted. Periapical disease is caused by opportunistic patho-
gens infecting the dental pulp and periapical tissues there-
fore the treatment of the disease involves elimination of
microorganisms in the course of endodontic treatment.
The activity of the microorganisms is associated with host
response [15–19].
The aim of the study was to determine the relationship
between the size of chronic inflammatory periapical lesions
and the inflammatory markers (hsCRP, IL-6, TNF-α level),
and lipids, and lipoproteins (LpPLA2, apolipoprotein (apo)




The study comprised 43 patients admitted to the Depart-
ment of Conservative Dentistry with Endodontics at the
Medical University of Lublin and a private dental practice.
The study was conducted in accordance with the guide-
lines of the Ethics Committee of the Medical University in
Lublin, Poland. The patients were in a good health condi-
tion. They (n = 43) were divided into groups: one up to
50 years of age and the other over 50 years of age. A
separate subgroup of the studied patients was that of
the oldest age and with the largest CAP lesions size. ApoAI
above 150 mg/dL and below 150 mg/dL as an important
criterion for the division into groups of patients was used.
A periapical X-ray of each tooth with apical inflammatory
lesion was taken by using of a sensor holder and the Kodak
digital radiography system. The size of the lesions (mm2)
was measured using the Kodak digital imaging system
software. If more than one periapical lesion was found
in a patient, the surfaces of all lesions were summed
up. All patients were without statin therapy. Patients
with CAP did not have periodontal disease and did not
receive lipid-lowering drugs, nine patients were taking
antihypertensive medications that do not effect on lipids.
No patient had diabetes, a liver or kidney disease, cancer,
acute inflammation, a stroke and acute cardiovascular
events. They did not habitually drink alcohol and did not
smoke tobacco. The control group consisted of 20 clinic-
ally healthy students and volunteers from the laboratory
(9 men and 11 women) aged from 23 to 50 years without
CAP. The absolute selection criteria in this group of pa-
tients were normal BMI, correct results of routine labora-
tory parameters, hsCRP, lipids, lipoproteins apoAI and
apoB lipid and lipoprotein ratios.
Sample preparation
Whole blood from the patients was drawn after 14 h of
fasting. The blood was taken from a vein in to commercial
test tubes. Red blood cells were separated from plasma by
centrifugation at 6000 rpm for 15 min at 4 °C (Eppendorf
Centrifuge 5810R). Serum was immediately separated and
stored in aliquots at 80 °C until use.
Detection of lipids, lipoproteins, hsCRP
Lipids, lipoproteins, and inflammatory markers were ob-
tained from serum after 14-h overnight fasting. Lipids
were measured on a Siemens analyzer (Germany). Clinical
parameters are listed in Table 1. Low density lipoprotein
cholesterol (LDL-C) was calculated according to the Frie-
dewald formula. Non-high density lipoprotein cholesterol
(non-HDL-C) was calculated as total cholesterol (TC)
minus HDL-C. Lipoproteins apoAI, apoB, hsCRP were
determined by immunonephelometric methods, using
the Health Care Diagnostic Product (Siemens GmbH,
Germany) on a Dade Behring nephelometer BNII System
(Germany) [20].
Detection of IL-6, TNF-α and LpPLAG7
Serum IL-6, TNF-α and LpPLA2G7 assay kits (ELISA,
R&D Systems) were used. The kit is a sandwich enzyme
immunoassay for in vitro quantitative measurement of
human IL-6 or TNF-α or LpPLA2G7 of serum. A mono-
clonal antibody specific for IL-6 or TNF-α or LpPLA2G7
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was pre-coated on to a microplate. Standards and sam-
ples were pipetted into wells, and any IL-6 or TNF-α or
LpPLA2G7 present was bound by immobilized antibody.
After washing away any unbound substances, enzyme-
linked polyclonal antibody specific for IL-6 or TNF-α or
LpPLA2G7 was added to the wells. After an incubation
period amplifier solution was added to the wells, and the
colour developed in proportion to the amount of IL-6 or
TNF-α or LpPLA2G7 bound in the initial stage. The
colour development was stopped and the intensity of the
color was measured.
Statistical analysis
The data were expressed as medians and minimum-
maximum. Statistical analysis of the results was performed
using the non-parametric Kruskal-Wallis (KW) test for
comparison of the CAP patient groups and the control
group. The relation between the CAP lesion size and the
inflammatory markers (hsCRP, IL-6, TNF-α level), and
lipids (triglycerides (TG), TC, LDL-C, HDL-C, nonHDL-C)
and lipoproteins (LpPLA2, apoAI, apoB concentration),
and lipoprotein ratios were examined by Spearman’s cor-
relation analysis. The statistical significance of all variables
was established at p < 0.05 and the statistical analysis were
performed using the STATISTICA software (StatSoft,
Krakow, Poland).
Ethics statement
Written informed consents were obtained from all the
participants. The study was approved by the Ethics
Committee of the Medical University in Lublin, Poland
and conducted according to the principles outlined in the
Declaration of Helsinki.
Results
Table 1 shows the selected clinical parameters in control
group, the groups of patients under and over 50 years of
age with CAP. The studies showed that in patients under
50 years of age there was no statistically significant in-
crease in the IL-6 and TNF-α concentration as compared
to controls, but there was a significant difference between
the concentration of hsCRP and LpPLA2 (Table 2). The
patients over 50 years of age and their aging showed a sig-
nificantly large size of CAP lesion and concentration of
IL-6 and TNF-α, hsCRP and LpPLA2, and these parame-
ters were the highest in the oldest patients with the largest
size of CAP lesion. Table 3 shows the lipid, lipoprotein,
and lipid and lipoprotein ratios in the control group and
patients under and over 50 years of age and the oldest
Table 1 Clinical parameters in the control group, in the group of patients≤ 50 years of age and > 50 years of age and in all patients
with chronic apical periodontitis (CAP), median (min- max)
Control Group Patients≤ 50 years of age Patients > 50 years of age All patients
n = 20 n = 20 n = 23 n = 43
Age, years 40(32–50) 41(32–50) 63(58–69)* 61(32–69)*
Sex (male, female) 9 M, 11 F 9 M, 11 F 13 M, 10 F 22 M, 21 F
BMI kg/m2 23(21–25) 23(20–28) 25(21–38)* 24(20–38)
Hypertension - 3 6 9
Statin therapy - - - -
P < 0.05-* vs control group
Table 2 Selected clinical parameters, the size of CAP lesion and the concentration of inflammatory markers in the control group, in
patients with ≤ 50 years of age and with > 50 years of age, in subgroup of patients with oldest age and the largest the size of CAP
lesion, and the group of all patients, the median (min- max)
Control group Patients ≤ 50 years of age Patients >50 years of age Oldest patients with
the largest sCAP
All patients
n = 20 n = 20 n = 23 n = 15 n = 43
Age 40(32–50) 41(32–50) 63(58–69)*,*** 65(58–69)*,*** 61(32–69)*,***
BMI (kg/m2 ) 23(21–25) 23(20–28) 25(21–38) 26(22–38)* 24(20–38)
sCAP - 24(4–56) 32(9–120),*** 34(23–120),*** 32(4–120),***
IL6 (pg/ml) 0.35(0.22–0.55) 0.56(0.13–2.09) 1.17(0.24–4.20)* 1.23(0.40–4.20)* 1.06(0.13–4.20)*
TNF-α (pg/ml) 1.09(0.42–1.55) 1.95(0.31–6.68) 3.96(0.83–8.77)* 4.97(0.92–8.77)*,*** 3.37(0.31–8.77)*
LpPLA2(ng/ml) 57(32–93) 153(32–328)* 200(98–328)* 213(172–275)* 188(32–328)*
hsCRP mg/L 0.014(0.017–0.075) 0.268(0.017–0.620)** 0.367(0.010–1.10)**,*** 0.424(0.010–1.10**,*** 0.338(0.010–1.10)**,***
P < 0.05-*; p < 0.01-** - vs control group; p < 0.05-*** - vs. patients > 50 years of age
sCAP - the size of chronic apical periodontitis lesion
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with the largest size of CAP lesion. These studies con-
firmed our observations that patients under 50 years of
age had the smallest CAP lesion size and did not show
statistically significant differences in the concentration
of lipids, apoAI, apoB and in the values of lipid and
lipoprotein ratios. Moreover, patients over 50 years of
age and the oldest with the largest size of CAP lesion
had significantly increased lipid and lipoprotein ratios
that suggested the risk of atherosclerosis in them. In
the studied groups of patients the concentration of
lipids, apoAI and apoB did not change as compared to
controls, but they showed a significant divergence of
the tested parameters from very low to very high, which
indicated dyslipidaemia and dyslipoproteinaemia in these
patients. Table 4 shows the clinical parameters, the CAP
lesion size, markers of inflammation and LpPLA2 mass in
the control group and patients with apoAI ≥ 150 mg/dL,
with apoAI ≤ 150 mg/dL level and in all patients. The ex-
tent of CAP lesion size was similar in all patient groups.
In patients with apoAI level ≥ 150 mg/dL the level of
LpPLA2 and hsCRP was evaluated, but not the concentra-
tion of IL-6 and TNF-α as compared to control. In pa-
tients with apoAI ≤ 150 mg/dL the level of all markers of
inflammation was significantly elevated in relation to con-
trol, and the level of TNF-α and hsCRP was significantly
higher in relation to patients with apoAI ≥ 150 mg/dL
level. Table 5 shows the concentration of lipids, apoAI,
apoB, ratios of lipid and lipoprotein in the control group
of patients with apoAI ≥ 150 mg/dL and apoAI ≤ 150 mg/dL
level. In patients with apoAI level ≥150 mg/dL no change in
lipids, apoAI, apoB concentration and the values of
lipid and lipoprotein ratios was shown, but in those
with apoAI ≤ 150 mg/dL level significant differences in
HDL-C, apoAI and apoB level and of lipid and lipopro-
tein ratios were shown, which indicated a risk of ath-
erosclerosis and coronary heart diseases.
In all the tested patients a significant positive correl-
ation was shown between:
Table 3 Concentration of lipid, apoAI, apoB and lipid and lipoprotein ratios in the control group, patients≤ 50 years of age and >
50 years of age, and in subgroup patients with oldest age and the largest the CAP lesion size and in all patients, the median (min- max)
Control group Patients≤ 50 years of age Patients >50 years of age Oldest patients with the largest sCAP All patients
n = 20 n = 20 n = 23 n = 15 n = 43
TG (mmol/L) 1.07(0.70–1.94) 1.27(0.65–3.37) 1.45(0.58–4.26) 1.34(0.58–4.26) 1.33(0.58–4.26)
TC (mmol/L) 4.92(4.35–5.69) 5.12(4.06–7.20) 5.51(3.80-7.40) 5.43(4.25–7.40) 5.38(3.80–7.40)
LDL-C (mmol/L) 3.15(2.20–3.62) 3.60(2.36–5.20) 4.06(2.14–5.23) 3.85(2.69–4.71) 3.78(2.14–5.23)
HDL-C (mmol/L) 1.42(1.13–2.40) 1.37(0.62–2.07) 1.13(0.49–1.99) 1.08(0.49–1.86) 1.16(0.49–2.07)
nHDL-C (mmol/L) 3.62(2.53–4.19) 3.85(2.66–5.82) 4.29(2.64–6.21) 4.06(3.15–6.11) 3.93(2.64–6.21)
apoAI (mg/L) 1680(1500–2030) 1500(790–2350) 1440(950–1820) 1420(1050–1820) 1440(790–2350)
apoB (mg/L) 880(620–1060) 760(520–1340) 970(500–1490) 800(500–1490) 870(500–1490)
TC/HDL-C 3.45(2.17–4.45) 3.67(2.56–6.00) 4.82(2.69–9.0)* 5.01(2.69–9.27)* 4.63(2.56–9.27)
LDL/HDL-C 2.22(1.11–3.72) 2.62(1.35–6.53) 3.57(1.97–9.53)* 3.52(1.54–6.31)* 3.24(1.35–9.53)
TG/HDL-C 1.78(1.0–3.2) 2.13(0.97–8.28) 2.83(0.72–11.8)* 2.83(0.72–7.54)* 2.56(0.72–11.8)
HDL-C/apoAI 0.33(0.32–0.47) 0.35(0.23–0.66) 0.30(0.16–0.50) 0.29(0.0.16–0.48) 0.31(0.16–0.66)
apoAI/apoB 1.89(1.17–3.27) 1.82(1.17–3.17) 1.49(0.70–2.55)* 1.77(0.80–2.45) 1.65(0.70–3.17)
p < 0.05-*; sCAP - the size of chronic apical periodontitis lesion
Table 4 Clinical parameters, the size of CAP lesion and the concentration of inflammatory markers in the control group and patients
with apoAI ≥ 150 mg/dl and apoAI ≤ 150 mg/dl and all patients with CAP, median (min- max)
Control group Patients with apoAI≥ 150 mg/dl Patients with apoAI≤ 150 mg/dl All patients
n = 20 n = 18 n = 25 n = 43
Age 40(32–50) 55(32–69)* 61(37–69)* 61(32–69)
BMI (kg/m2 ) 23(21–25) 23(20–28) 25(21–38) 24(20–38)
sCAP (mm2) - 33(9.4–120) 32(4–50) 32(4–120)
IL6 (pg/ml) 0.35(0.22–0.55) 0.55(0.220–3.15) 1.14(0.13–4.20)* 1.06(0.13–4.20)*
TNF-α (pg/ml) 1.09(0.42–1.55) 1.21(0.31–8.77) 3.55(0.42–1.24)*,*** 3.37(0.31–8.77)*
LpPLA2(ng/ml) 57(32–93) 157(32–327)* 202(80–328)* 188(32–328)*
hsCRP mg/L 0.014(0.017–0.075) 0.155(0.010–0.789)** 0.378(0.010–1.10)**,*** 0.338(0.01–1.10)**,***
p < 0.05-* ; p < 0.01-** - vs control group; p < 0.05-*** - vs patients with apoAI ≥ 150 mg/dl
sCAP - the size of chronic apical periodontitis lesion
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the concentration of TNF- α and IL-6 level (R = 0.471,
p = 0.009), that of TNF - α and hsCRP level (R = 0.608,
p = 0.00004), that of TNF - α and the age (r = 0.460,
p = 0.013 ); the concentration of IL-6 and hsCRP level
(R = 0.403, p = 0.025), that of IL-6 and the age (r = 0.590,
p = 0.0007); the concentration of LpPLA2 and TG level
(R = 0.537, p = 0.0005), that of LpPLA2 and TC level
(R = 0.563, p = 0.0002), that of LpPLA2 and LDL-C level
(R = 0.655, p = 0.00008), that of LpPLA2 and nonHDL-C
level (R = 0.701 p = 0.000001), that of LpPLA2 and TC/
HDL-C ratio (R = 0.414, 0.009), that of LpPLA2 and TC/
HDL-C ratio (R = 0.418, p = 0.009), that of LpPLA2 and
LDL-C/HDL-C ratio (R = 0.430, p = 0.006) that of LpPLa2
and TG/HDL-C ratio (R = 0.406, p = 0.011), that of
LpPLA2 and the age (R = LpPLA2, p = 0.013).
In the group of patients under 50 years of age we found
a statistically significant positive correlation between
the size of CAP lesion and the concentration of apoAI
(R = 0.669; p = 0.012), and between TNF-α and hsCRP
(R = 0.690, p = 0.018).
In patients over 50 years of age statistically significant
correlations were found between: the size of CAP lesion
and LpPLA2 level (R = 0.493, p = 0.023), and the size of
CAP lesion and hsCRP level (R = 0.425, p = 0.043), and
significant correlations between the concentration of
TNF-α and hsCRP level (R = 0.624, p = 0.005), and between
the concentration of TNF-α and IL-6 level (R = 0.26,
p = 0.009). Moreover, between the concentration of
LpPLA2 and TG level (R = 0.437, p= 0.032), that of LpPLA2
and TC level (R = 0.473, p= 0.032), that of LpPLA2 and
LDL-C level (R = 0.518, p= 0.009), LpPLA2 and nonHDL-C
(R = 0.573, p= 0.003), and between that of IL-6 and the age
(0.597, p= 0.0015).
In patients with apoAI ≤ 150 mg/dL, statistically signifi-
cant positive correlations was found between: the CAP
lesion size and LpPLA2 level (R = 0.719, p = 0.0003) and
the CAP lesion size and the age (R = 0.776, p = 0.0001)
and between the CAP lesion size and TG level (R = 0.515,
p = 0.011), and the CAP lesion size TG/HDL-C ratio
(R = 0.414, p = 0.04).
However, in patients with apoAI ≥ 150 mg/dL level a
negative correlation between the size of CAP lesion and
LpPLA2 level (R = −0.727, p = 0.007) was found.
Discussion
The literature data indicate how much incomplete are
the studies on chronic infections in periodontal diseases,
and particularly in chronic apical periodontitis. In recent
years the concept of focal infection has changed, and
mostly shows the correlation between chronic periodontal
inflammation and systemic diseases [15, 16, 21–23]. The
patients in our research were generally in good health
condition without acute periodontal diseases and infec-
tions, caring for oral hygiene. It should be also noted that
our patients did not take statins. Because the patient’s age
varied (32–69 years) the size of CAP lesion were differ-
ent. The results showed that the concentration of in-
flammatory markers (concentration of IL-6, TNF-α,
hsCRP), and LpPLA2 and the size of CAP lesion were
significantly the lowest in patients under 50 years of
age, increased with age, and were the highest in relation
to the control group, and patients ≤ 50 years of age as
well as the oldest with largest CAP lesion size. These
studies are consistent with the previous observations
that the patient’s age has an impact on the healing
process of chronic inflammation of apical teeth [24].
Table 5 Lipids, apoAI, apoB level and lipid and lipoprotein ratios in the control group and patients with apoAI ≥150 mg/dL,
apoAI ≤150 mg/dL and all patients with CAP, median (min- max)
Control group Patients with apoAI ≥150 mg/dl Patients with apoAI ≤ 150 mg/dl All patients
n = 20 n = 18 n = 25 n = 43
TG (mmol/L) 1.07(0.70–1.94) 1.27(0.58–1.84) 1.45(0.65–4.26) 1.33(0.58–4.26)
TC (mmol/L) 4.92(4.35–5.69) 5.49(4.19–7.20) 5.28(3.80–7.40) 5.38(3.80–7.40)
LDL-C (mmol/L) 3.15(2.20–3.62) 4.04(2.20–4.71) 3.72(2.14–5.23) 3.78(2.14–5.23)
HDL-C (mmol/L) 1.42(1.13–2.40) 1.52(1.19–2.07) 1.08(0.49–1.50)*,*** 1.16(0.49–2.07)
nHDL-C (mmol/L) 3.62(2.53–4.19) 4.06(2.53–5.23) 4.35-(2.64–6.21) 3.93(2.64–6.21)
apoAI (g/L) 1680(1500–2030) 1740(1500–2350) 1340(790–1480)*,*** 1440(790–2350)
apoB (g/L) 880(620–1060) 760(520–1280) 86(0500–1490) 870(500–1490)
TC/HDL-C 3.45(2.17–4.45) 3.58(2.56–4.82) 4.92(2.68–9.27)* 4.63(2.56–9.27)*
LDL/HDL-C 2.22(1.11–3.72) 2.64(1.35–3.54) 3.50(1.80–9.53)* 3.24(1.35–9.53)*
TG/HDL-C 1.72(1.0–3.2) 1.91(0.72–3.26) 3.09(1.07–11.82)* 2.56(0.72–11.82)*
HDL-C/apoAI 0.33(0.32–0.47) 0.33(0.27–0.51) 0.31(0.16–0.66) 0.31(0.16–0.66)
apoAI/apoB 1.89(1.17–3.27) 2.28(1.36–3.27) 1.56(0.70–2.55)* 1.65(0.70–3.17)
p < 0.05-*- vs control group
p < 0.05-*** - vs apoAI ≥ 150 mg/dl
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The studies of Starr et al. [25] showed that the adipo-
cytes adipose tissue is the cause of elevated IL-6 and
TNF-α levels, which may give rise to inflammation,
tendency to infections, atherosclerosis and heart
diseases.
A considerable differentiation of the concentration data
of lipids, apoB, and apoAI indicates that there were
patients with dyslipidaemia and dyslipoproteinaemia
characterized by elevated levels of atherosclerotic lipid
and lipoprotein profiles. Therefore, all patients were
divided into groups with apoAI ≥ 150 mg/dL and
apoAI < 150 mg/dL level. In patients with apoAI ≤
150 mg/dL the IL-6, TNF-α, hsCRP and LpPLA2 con-
centration were significantly higher as compared to
the patients with apoAI ≥ 150 mg/dL level and control
group, whereas the size of CAP lesion was similar in
both studied patient groups. The concentration of lipid
and lipoprotein was still various, but it was worse in pa-
tients with apoA ≤ 150 mg/dL concentration. The results
indicated that the increasing level of LpPLA2 and inflam-
matory markers and decreased apoAI concentration could
cause systemic infections and diseases in all patients re-
gardless of the age. These studies also suggested that
dyslipidaemia and dyslipoproteinaemia depend on indi-
vidual patient’s condition, his environmental and gen-
etic predisposition to the occurrence of atherosclerosis,
heart diseases, stroke, kidney diseases, which together
with acquired dysfunctions with age pose a serious threat
to the health and life of such patients [21]. In all patients
we showed a strong positive correlation between the con-
centration of TNF-α and IL-6 level, and that of TNF-α
and hsCRP level. IL-6 level correlated positively with
hsCRP concentration and age. These results are consistent
with the studies of other authors [26]. A positive relation-
ship was demonstrated between the concentration of
LpPLA2 and lipids (TG, TC, LDL-C and nonHDL-C) and
that of LpPLA2 and lipid ratios (TC/HDL-C, LDL-C/
HDL-C, TG/HDL-C) and between that of LpPLA2 and
the patient’s age. These positive correlations indicated that
together with increasing concentration of LpPLA2, the
lipids (TG, TC, LDL-C and nonHDL-C) and atherogenic
lipid and lipoprotein ratios also increased, that suggested a
risk of atherosclerosis in these patients [27]. Moreover, in
the group of patients over 50 years of age a positive correl-
ation between the size of CAP lesion and hsCRP concen-
tration and between the size of CAP lesion and LpPLA2
level was shown. The correlations indicated that the in-
flammation might increase the concentration of TC, TG,
LDL-C, nonHDL-C and LpPLA2 and suggested that the
inflammation might induce dyslipoproteinaemia and in-
crease TG in triglyceride-rich lipoprotein and TC in
cholesterol-rich lipoprotein, which could be effected by
dysfunction of the vessel wall. These correlations may
explain a high concentration of TC, nonHDL-C, TG,
LDL-C and apoB in some patients with CAP [2, 11–13, 28].
Elevated Lp-PLA2 mass was related with endothelial dys-
function, carotid atherosclerosis, impaired coronary flow re-
serve and increased arterial stiffness and adverse outcome in
CVD patients [12]. Plasma (Lp-PLA2) binds to low-density
lipoprotein. The levels of Lp-PLA2 reflected the plaque bur-
den, and are up-regulated in acute coronary syndrome
(ACS). Lp-PLA2 levels were related to plaque stability and
they might be a diagnostic biomarker for ACS [13]. In the
group of patients with CAP under 50 years of age a positive
correlation between the level of TNF-α and hsCRP concen-
tration indicated increased activity of inflammatory markers.
Moreover, our studies showed a positive correlation between
the concentration of apoAI and the size of CAP lesion, and
a negative correlation between the size of CAP lesion and
LpPLA2 level. This positive correlation between the
size of CAP lesion and apoAI level may suggest limiting
CAP lesion size and the risk of systemic infections in
young patients with high concentration of apoAI, and
high antiinflammatory functions of apoAI and HDL parti-
cles [27–29]. A negative correlation between size of CAP
lesion and LpPLA2 level may also suggest antiinflam-
matory function of LpPLA2, and limiting the size of CAP
lesion and systemic risk of infections in patients with
elevated concentration of apoAI, especially in younger
people. We report for the first time that both LpPLA2
level and apoAI concentration can limit inflammation
spread in patients with CAP. Several lines of evidence
suggest that the role of plasma Lp-PLA2 in atheroscler-
osis may depend on the type of lipoprotein particle with
which this enzyme is associated. The HDL-associated
Lp-PLA2 may express anti-atherogenic activities and is
also independently associated with a lower risk of cardiac
death [27]. Thus, our studies suggest that the prognostic
role of Lp-PLA2 in chronic CVD may be explained by a
generalized detrimental effect of lipase on the endothelial
function and arterial wall properties [12]. It appears that
periodontitis induces proatherogenic lipoprotein patterns,
and the association turns out to be the strongest for apoB-
100-containing lipoproteins, but details about the poten-
tial mechanisms and the specific role of VLDL in this
context have remained largely unknown [9, 30]. Rufail et al.
[31] showed increased TG in cases of periodontitis as a
result of increases in VLDL and a more robust increase
in IDL particles, which appears to be more predictive of
atherosclerosis progression than LDL, leading to increased
cardiovascular (CV) risk in these subjects. Pussinen al.
[32] indicated that periodontal infections may alter the
antiatherogenic potency of HDL, indicating that HDL may
effect the CV risk of subjects in ways that are not re-
lated to the concentration of these particles. The authors
present that lipoproteins (especially HDL) are effective
in binding and neutralizing lipopolysaccharide (LPS) of
Gram-negative bacteria, limiting thereby the expression
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of cytokines and lipid peroxidation, and have an anti-
oxidant feature. However, the protective role of HDL
may be related not only to the level but also to the quality
of HDL [9, 33]. Recently Petersen et al. [34] reported that
CAP correlated positively with the aortic atherosclerotic
burden. In the regression models, CAP without endodon-
tic treatment was found to be an important factor, but
not in apical radiolucencies of teeth with endodontic
treatment.
Conclusions
The findings suggest that in patients with CAP together
with aging the size of CAP lesion and the concentration
of inflammatory markers and LpPLA2 mass increase.
The correlation between CAP lesion size and LpPLA2
and between CAP lesion size and TG level can cause in-
crease TG in atherogenic apoB-containing triglyceride-
rich lipoprotein and TC in cholesterol-rich lipoprotein.
The patients with low levels of apoAI and high LpPLA2
can have a higher risk of odontogenic diseases, the pro-
gression of atherosclerosis and coronary heart diseases.
Moreover, we have found a positive correlation between
apoAI level and the CAP lesion size and a negative cor-
relation between LpPLA2 level and the CAP lesion size.
The results suggest for the first time that apoAI and
LpPLA2 in HDL particles have antiinflammatory action
and together can limit the CAP lesion size in patient with
a higher apoAI level. The literature data on the distribu-
tion of lipoprotein particles in subjects are still insuffi-
cient, so this problem requires further investigations.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AK and MS-D performed the experiments, and drafting the manuscript. TB
and EK have planned the study, performed data analysis and interpretation,
and revision of the manuscript. All authors have read and approved the final
version of the article.
Author details
1Department of Conservative Dentistry with Endodontic, Medical University,
Karmelicka 7, 20-081 Lublin, Poland. 2Department of Laboratory Diagnostics,
Medical University, Street Chodźki 1, 20-093 Lublin, Poland.
Received: 4 October 2015 Accepted: 16 November 2015
References
1. Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W Jr, Rosenfeld ME, et al.
A definition of initial, fatty streak, and intermediate lesions of
atherosclerosis. A report from the Committee on Vascular Lesions of the
Council on Arteriosclerosis, American Heart Association. Circulation. 1994;89(5):
2462–78.
2. Ross R. Atherosclerosis–an inflammatory disease. New Engl J Med.
1999;340(2):115–26.
3. Fentoglu Ö, Kırzıoglu FY, Özdem M, Kocak H, Sütcü R, Sert T. Proinflammatory
cytokine levels in hyperlipidemic patients with periodontitis after periodontal
treatment. Oral Dis. 2012;18:299–306.
4. Turner MD, Nedjai B, Tara Hurst A, Pennington DJ. Cytokines and chemokines:
At the crossroads of cell signaling and inflammatory disease. Biochim Biophys
Acta. 2014;1843(11):2563–82.
5. Scheller J, Ohnesorge N, Rose-John S. Interleukin-6 Trans-Signaling in
Chronic Inflammation and Cancer. Scand J Immunol. 2006;63(5):321–9.
6. Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A, et al.
Elevated circulating free fatty acid levels impaire endothelium-dependent
vasodilation. J Clin Invest. 1997;100(5):1230–9.
7. Van der Poll T, Levi M, Hack CE, ten Cate H, Van Deventer SJ, Eerenberg AJ,
et al. Elimination of interleukin 6 attenuates coagulation activation in
experimental endotoxemia in chimpanzees. J Exp Med. 1994;179(4):1253–9.
8. Cutler CW, Shinedling EA, Nunn M, Jotwani R, Kim BO, Nares S, et al.
Association between periodontitis and hyperlipidemia: cause or effect? J
Periodontol. 1999;70(12):1429–34.
9. Mesa F, Magán-Fernández A, Nikolic D, Marfil-Alvarez R, Nibali L, Rizzo M.
Periodontitis, blood lipids and lipoproteins. Clin Lipidol. 2014;9(2):261–76.
10. Rizzo M, Kotur-Stevuljevic J, Berneis K, et al. Atherogenic dyslipidemia and
oxidative stress: a new look. Transl Res. 2009;153(5):217–23.
11. Liu J, Wang W, Qi Y, Yong O, Zhou G, Wang M, et al. Associated between
the lipoprotein associated –phospholipase A2 activity and the progression
of subclinical atherosclerosis. J Atheroscler Thromb. 2014;21(6):532–42.
12. Ikonomidis I, Kadoglou NNP, Tritakis V, Paraskevaidis I, Dimas K, Trivilou P, et al.
Association of Lp-PLA2 with digital reactive hyperemia, coronary flow
reserve, carotid atherosclerosis and arterial stiffness in coronary artery
disease. Atherosclerosis. 2014;234(1):34–4.
13. Chung H, Kwon HK, Kim J-Y, Yoon YW, Rhee J, Choi E-Y, et al.
Lipoprotein-associated phospholipase A2 is related to plaque stability
and is a potential biomarker for acute coronary syndrome. Yonsei Med J.
2014;55(6):1507–15.
14. Losche W, Marshal GJ, Apatzidou DA, Krause S, Kocher T, Kinane DF.
Lipoprotein-associated phospholipase A2 and plasma lipids in patients with
destructive periodontal disease. J Clin Periodontol. 2005;32(6):640–4.
15. Segura-Egea JJ, Martin-Gonzalez JM, Castellanos-Cosano L. Endodontic
medicine: connections between apical periodontitis and systemic diseases.
Int Endodont J. 2015;48:933–51.
16. Van der Waal SV, Lappin DF, Crielaard W. Does apical periodontitis have
systemic consequences? The need for well-planned and carefully conducted
clinical studies. Br Dent J. 2015;218:513–6.
17. Niedzielska I, Chudek J, Kowal I, Słabiak-Blaz N, Kolonko A, Kuczera P, et al.
The odontogenic-related micro inflammation in patients with chronic
kidney disease. Ren Fail. 2014;36(6):883–8.
18. Graunaite I, Lodiene G, Maciulskiene V. Pathogenesis of apical periodontitis:
a literature review. J Oral Maxillofac Res. 2011;2(4), e1.
19. Jakovljeviv A, Knezevic A, Karalic D, Soldatovic I, Popovic B, Milasin J, et al.
Pro-inflammatory cytokine levels in human apical periodontitis: correlation
with clinical and histological findings. Aust Endod J. 2015;41:72–7.
20. Kimak E, Hałabiś M, Baranowicz-Gąszczyk I. Relationships between serum
lipid, lipoprotein, triglyceride-rich lipoprotein, and HDL particle concentrations
in post-renal transplant patients. JZUS-B. 2010;11(4):249–57.
21. Pizzo G, Guiglia R, Lo Russo L, Campisi G. Dentistry and internal medicine:
from the focal infection theory to the periodontal medicine concept. Eur J
Intern Med. 2010;21(6):496–502.
22. Grönholm L, Lemberg KK, Tjäderhane L, Lauhio A, Lindqvist C, Rautemaa-
Richardson R. The role of unfinished root canal treatment in odontogenic
maxillofacial infections requiring hospital care. Clin Oral Invest. 2013;17(1):113–21.
23. Griffiths R, Barbour S. Lipoproteins and lipoprotein metabolism in periodontal
disease. Clin Lipidol. 2010;5(3):397–411.
24. Trusewicz M, Buczkowska-Radlińska J, Lipski M, Dębicka P. The effect of age
on the process of healing of chronic periapical inflammation. Annal AMS.
2009;55(3):51–4.
25. Starr M, Evers B, Saito H. Age-associated increase in cytokine production
during systemic inflammation: adipose tissue as a major source of IL-6. J
Gerontol: Biol Sci. 2009;64A(7):723–30.
26. Zuliani G, Volpato S, Blaf A, Bandinelli S, Corsi AM, Lauretani F, et al. High
interleukin-6 plasma levels are associated with low HDL-C levels in community-
dwelling older adults: the in chianti study. Atherosclerosis. 2007;192(2):384–90.
27. Tellis CC, Tselepis AD. Pathophysiological role and clinical significance of
lipoprotein-associated phospholipase A2 (Lp-PLA2) bound to LDL and HDL.
Curr Pharm Des. 2014;20(40):6256–69.
28. Parhofer K. Increasing HDL-cholesterol and prevention of atherosclerosis: A
critical perspective. Atherosclerosis. 2015;18:109–11.
29. Dullaart RPF, Annema W, Tio RT, Tietge UJF. The HDL anti-inflammatory
function is impaired in myocardial infection and may predict new cardiac
events independent of HDL cholesterol. Clin Chim Acta. 2014;433:34–8.
Kimak et al. Lipids in Health and Disease  (2015) 14:162 Page 7 of 8
30. Kallio KA, Hyvarinen K, Kovanen PT, Jauhiainen M, Pussinen PJ. Very low
density lipoproteins derived from periodontitis patients facilitate macrophage
activation via lipopolysaccharide function. Metabolism. 2013;62(5):661–8.
31. Rufail ML, Schenkein HA, Barbour SE, Tew JG, Van Antwerpen R. Altered
lipoprotein subclass distribution and PAF-AH activity in subjects with
generalized aggressive periodontitis. J Lipid Res. 2005;46(12):2752–60.
32. Pussinen PJ, Jauhiainen M, Vilkuna-Rautiainen T, Sundvall J, Vesanen M, Mattila
K, et al. Periodontitis decreases the antiatherogenic potency of high density
lipoprotein. J Lipid Res. 2004;45(1):139–47.
33. Khera AV, Cuchel M, De La Llera-Moya M, Rodrigues A, Burke MF, Jafri K,
et al. Cholesterol efflux capacity, high-density lipoprotein function, and
atherosclerosis. N Engl J Med. 2011;364(2):127–35.
34. Petersen J, Glaßl EM, Nasseri P, Crismani A, Luger AK, Schoenherr E, et al.
The association of chronic apical periodontitis and endodontic therapy with
atherosclerosis. Clin Oral Invest. 2014;18:1813–23.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Kimak et al. Lipids in Health and Disease  (2015) 14:162 Page 8 of 8
